To analyze the CDC of SBU-CD55 × CD20, which has an asymmetric structure capable of binding to CD55 and CD20 simultaneously, we used two rituximab-sensitive cell lines (Ramos and WSU-NHL) and two rituximab-resistant cell lines (in-house developed Ramos-RR and BJAB). This evidence concerns the gene CD55 and non-Hodgkin lymphoma.